| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2817954cd008bcd609a4c4eb49050be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c14e4fb353fa229bc9c2f7fae494e990
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9e4bfa6b7131aa040cdf49cdb20b883 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2017-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86835c3ad60895ae42fb42f13671ae81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_666c4529ff15997048e5df8b962177ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13c74fbf68fdf958a80dbcf3b05ea3b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9936a6b46ffa695adf3ff0a7d231209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a9a23f81d1496d7380251d9076e44f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe35b3cb7d560e03cb787f38d89483e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb9956ff69529dd76a51299b37137e4e |
| publicationDate |
2018-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018078143-A1 |
| titleOfInvention |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy |
| abstract |
The present invention relates to a method for determining the susceptibility/responsiveness of (a) cancer cell(s), preferably (a) colorectal cancer cell(s), to the treatment with an epidermal growth factor receptor (EGFR) inhibitor. Further, the present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) tumor sample(s) of colorectal cancer (CRC) with susceptibility to an epidermal growth factor receptor (EGFR) inhibitor. Furthermore, an in vitro method for the identification of a responder for or a subject, preferably a human patient, suffering from colorectal cancer (CRC) to an epidermal growth factor receptor (EGFR) inhibitor is disclosed. The present invention also relates to a method of monitoring the efficacy of a treatment of the colorectal cancer (CRC) with an epidermal growth factor receptor (EGFR) inhibitor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021077080-A3 |
| priorityDate |
2016-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |